Atogepant
Brand names: Qulipta · Active ingredient: Atogepant
In short: QULIPTA is indicated for the preventive treatment of migraine in adults.
What is Atogepant used for?
QULIPTA is indicated for the preventive treatment of migraine in adults.
Atogepant dosage
QULIPTA is taken orally with or without food.
Episodic Migraine
The recommended dosage of QULIPTA for episodic migraine is 10 mg, 30 mg, or 60 mg taken once daily.
Chronic Migraine
The recommended dosage of QULIPTA for chronic migraine is 60 mg taken once daily.
Dosage modifications and usage recommendations for episodic and chronic migraine with concomitant use of specific drugs and for patients with renal impairment are provided in Table 1.
Table
1
: Dos
age
Modifications for Drug Interactions and for Specific Populations
Dosage Modifications | Recommended Once Daily
Dosage for
Episodic Migraine | Usage and
Recommended
Once Daily
Dosage for
Chronic Migraine
Concomitant Drug
Strong CYP3A4 Inhibitors (
7.1
) | 10 mg | 10 mg
Strong CYP3A4 Inducers (
7.2
) | 60 mga | Not recommended
Moderate CYP3A4 Inducers (
7.2
) | 60 mg | Not recommended
Weak CYP3A4 Inducers (
7.2
) | 30 mg or 60 mg | 60 mga
OATP Inhibitors (
7.3
) | 10 mg or 30 mg | 30 mg
Renal Impairment
Severe Renal Impairment and End-Stage Renal Disease (CLcr <30 mL/min) (
8.6
) | 10 mg | Not recommended
a Coadministration decreases atogepant exposure. Monitor for reduced efficacy.
How to take Atogepant — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Hypersensitivity Reactions
Inform patients about the signs and symptoms of hypersensitivity reactions and that these reactions can occur with QULIPTA. Advise patients to discontinue QULIPTA and seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction .
Hypertension
Inform patients that hypertension can develop or pre-existing hypertension can worsen with QULIPTA, and that they should contact their healthcare providers if they experience elevation in their blood pressure .
Raynaud’s Phenomenon
Inform patients that Raynaud’s phenomenon can develop or worsen with QULIPTA. Advise patients to discontinue QULIPTA and contact their healthcare provider if they experience signs or symptoms of Raynaud’s phenomenon .
Drug Interactions
Inform patients that QULIPTA may interact with certain other drugs, and that dosage modifications of QULIPTA may be recommended when used with some other drugs. …
Warnings & precautions
Do not take this medicine if: QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA. Reactions have included anaphylaxis and dyspnea .
Hypersensitivity reactions, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA . Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy .
Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including QULIPTA, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension and, in some cases, hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. QULIPTA was discontinued in many of the reported cases.
Monitor patients treated with QULIPTA for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of QULIPTA is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.
Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including QULIPTA. In reported cases with small molecule CGRP antagonists, symptom onset occurred a median of 1.5 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. …
Atogepant side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hypersensitivity Reactions
Hypertension
Raynaud’s Phenomenon
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of QULIPTA was evaluated in 2657 patients with migraine who received at least one dose of QULIPTA. Of these, 1225 patients were exposed to QULIPTA for at least 6 months, and 826 patients were exposed for 12 months.
In the 12-week, placebo-controlled clinical studies (Studies 1, 2, and 3), 314 patients received at least one dose of QULIPTA 10 mg once daily, 411 patients received at least one dose of QULIPTA 30 mg once daily, 678 patients received at least one dose of QULIPTA 60 mg once daily, and 663 patients received placebo . Approximately 88% were female, 75% were White, 13% were Black, 10% were Asian, and 10% were of Hispanic or Latino ethnicity. The mean age at study entry was 41 years (range 18 to 74 years).
The most common adverse reactions (incidence at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.
Table 2 summarizes the adverse reactions that occurred during Studies 1, 2, and 3. …
Drug interactions
Coadministration of QULIPTA with itraconazole, a strong CYP3A4 inhibitor, resulted in a significant increase in exposure of atogepant in healthy subjects . The recommended dosage of QULIPTA with concomitant use of strong CYP3A4 inhibitors is 10 mg once daily . No dosage adjustment of QULIPTA is needed with concomitant use of moderate or weak CYP3A4 inhibitors.
Coadministration of QULIPTA with steady-state rifampin, a strong CYP3A4 inducer and OATP1B1 and OATP1B3 inhibitor, resulted in a significant decrease in exposure of atogepant in healthy subjects . Concomitant administration of QULIPTA with moderate inducers of CYP3A4 can also result in decreased exposure of atogepant. Coadministration of QULIPTA with steady-state topiramate, a weak CYP3A4 inducer, resulted in decreased exposure of atogepant in healthy subjects
.
For episodic migraine, the recommended dosage of QULIPTA with concomitant use of strong or moderate CYP3A4 inducers is 60 mg once daily. During concomitant use of QULIPTA with strong CYP3A4 inducers, monitor monthly for signs of reduced efficacy, and consider alternative therapies if a reduction in efficacy is observed. The recommended dosage of QULIPTA with concomitant use of weak CYP3A4 inducers is 30 mg or 60 mg once daily . …
About this medicine
The active ingredient of QULIPTA is atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. The chemical name of atogepant is (3’S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2’-oxo-1’,2’,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3’-pyrrolo[2,3-b]pyridine]-3-carboxamide, and it has the following structural formula:
The molecular formula is C29H2
3F6N5O3 and molecular weight is 603.5. Atogepant is a white to off-white powder. It is freely soluble in ethanol, soluble in methanol, sparingly soluble in acetone, slightly soluble in acetonitrile, and practically insoluble in water.
QULIPTA is available as tablets for oral administration containing 10 mg, 30 mg, or 60 mg atogepant. The inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.
How it works: Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8c8ab8f4-32bd-497a-befa-70c8a51d8d52. Read the full official label on DailyMed.
Related medicines
Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine